Nureca Limited Approves Annual Financial Results and Key Management Appointments
Nureca Limited announced the outcomes of its Board of Directors meeting held on May 29, 2026. The board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, while also finalizing key management appointments and strategic expansion plans.Financial Results for FY2026
The company disclosed its comprehensive financial results for the year ended March 31, 2026, along with the consolidated statement of assets and liabilities.Based on the submitted figures (Amounts in Rs. millions, unless otherwise stated), the consolidated financials showed the following key results:
| Particulars | Year Ended 31 March 2026 (Audited) | Year Ended 31 March 2025 (Audited) |
|---|---|---|
| Total Revenue from Operations | 354.05 | 396.40 |
| Total Income | 364.67 | 419.25 |
| Total Expenses | 426.19 | 378.77 |
| Profit / (Loss) before tax | (61.52) | 40.48 |
| Total Comprehensive Income / (Loss) | (65.74) | 32.31 |
| Profit / (Loss) after tax for the period | (66.25) | 32.31 |
The consolidated balance sheet data also reflected the following:
| Particulars | As at 31 March 2026 (Audited) | As at 31 March 2025 (Audited) |
|---|---|---|
| Total Assets | 1,935.44 | 2,061.59 |
| Total Equity | 1,771.60 | 1,924.79 |
| Total Liabilities | 163.84 | 136.80 |
Corporate Governance and Leadership Changes
The Board of Directors approved several appointments and changes to the company's leadership structure:- Internal Auditor Appointment: M/s MGSG and Associates, Chartered Accountants, were approved as the Internal Auditor for the Financial Year 2026-27.
- CFO Appointment: Mr. Chander Kant was approved for the role of Chief Financial Officer (CFO) and Key Managerial Personnel (KMP), effective from June 27, 2026. Mr. Kant is a strategic finance professional with over 13 years of experience across various industries.
- Director Reappointments:
* Mr. Saurabh Goyal (DIN: 00136037) was re-appointed as Managing Director for three years, effective September 03, 2026.
* Ms. Smita Goyal (DIN: 08929179) was appointed as Additional Director (Whole Time Director) for a period of three years, effective June 01, 2026.
* Mr. Aryan Goyal was also approved for re-appointment as a director who retires by rotation.
Key Managerial Personnel Departure: The board accepted the resignation of Mr. Naresh Gupta, Chief Financial Officer (CFO) and Key Managerial Personnel. His last working day is set for June 26, 2026.
Strategic Expansion and Investor Activities
On the strategic front, the Board took several decisions focused on growth and market presence:- Capital Expenditure: The board approved an incremental capital expenditure (capex) of up to 100 crores for enhancing plant and machinery. This investment is earmarked for manufacturing additional medical devices, healthcare consumables, and hygiene products at the existing company-owned industrial land in Sundran, Derabassi, Punjab.
- Land Acquisition: The board also approved the purchase of additional land adjoining the company-owned industrial land at Sundaran, Dera Bassi, Punjab, to support future expansion.
Annual General Meeting Details
The company announced that the 10th Annual General Meeting (AGM) will be held on Tuesday, July 28, 2026, via video conferencing (VC) or other audio visual means (OAVM). The company’s register of members and share transfer books will be closed from Wednesday, July 22, 2026, till Tuesday, July 28, 2026, for the purpose of the AGM. The cut-off date for remote e-voting is Tuesday, July 21, 2026.NURECA Stock Price Movement
On Friday, Nureca Limited shares gained 3.34% to close at ₹281.45, marking an increase of ₹9.10 from the previous session. The equity saw trading volume of 17,255 shares, holding to an intraday range between a low of ₹272.4 and a high of ₹287.05.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: